2. Academic Validation
  3. A preclinical candidate of cyclophilin D inhibition improves alcohol-associated liver injury

A preclinical candidate of cyclophilin D inhibition improves alcohol-associated liver injury

  • Cell Rep Med. 2026 Mar 17;7(3):102654. doi: 10.1016/j.xcrm.2026.102654.
Zhaoyi Che 1,  Zhihui Luo 2,  Dong Xiao 3,  Fashu Ma 3,  Haoxiong Zhou 4,  Yali Song 5,  Shanshan Guo 3,  Yuan Yuan 6,  Hao Wang 1,  Ching-Pong Mak 3,  Kwok-Fai So 7,  Jia Xiao 8
Affiliations

Affiliations

  • 1 Department of Anesthesiology and Clinical Research Institute, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China.
  • 2 Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, China.
  • 3 Farsight Medical Technology (Shanghai) Co., Ltd., Shanghai 201210, China.
  • 4 Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
  • 5 Department of Ultrasound, Huadu District People's Hospital of Guangzhou, Guangzhou 510800, China.
  • 6 Aier Institute of Ophthalmology, Central South University, Changsha 410015, China.
  • 7 Joint International Research Laboratory of CNS Regeneration, Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou 510632, China.
  • 8 Department of Anesthesiology and Clinical Research Institute, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China; School of Life and Health Sciences, University of Health and Rehabilitation Sciences, Qingdao 266300, China. Electronic address: [email protected].
PMID: 41850244 DOI: 10.1016/j.xcrm.2026.102654
Abstract

Currently, no therapies are approved for alcohol-associated liver disease (ALD). Here, we identify Cyclophilin D (CypD) as a critical mediator in the progression of ALD. We observe elevated expression of CypD in ALD patients and a corresponding mouse model. Hepatocyte-specific knockout of CypD mitigates hepatic mitochondrial dysfunction, steatosis, inflammation, and oxidative stress. Conversely, overexpression of CypD exacerbates hepatic mitochondrial stress. In vivo and in vitro experiments demonstrate that a CypD inhibitor, RN-0001, effectively and safely alleviates hepatic damage induced by ethanol exposure; these protective effects are absent in CypD-deficient mice. Biophysical assays indicate that RN-0001 directly binds to CypD. Additionally, absorption, distribution, metabolism, excretion, and toxicity (ADMET) tests and first-in-human phase I clinical trial identify RN-0001 as a promising translational candidate for ALD therapy. Collectively, our study highlights the pathological role of CypD in ALD and introduces a preclinical candidate for its management. This study was registered at chictr.org.cn (ChiCTR2500106709).

Keywords

alcohol-associated liver disease; cyclophilin D; mitochondrial dysfunction; preclinical candidate.

Figures
Products
Inhibitors & Agonists
Other Products